# AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-datroway-approved-in-the-us-for-metastatic-breast-cancer/4121184243
- Published: 2025-01-20T07:35:22+00:00
- Author: Amilia Stone

First approval in the US for **[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo’s Datroway based on TROPION-Breast01 results showing 37% reduction
in the risk of disease progression or death vs. chemotherapy

_Datroway_ (datopotamab deruxtecan or Dato-DXd) has been approved in the US for 
the treatment of adult patients with unresectable or metastatic hormone receptor(
HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have
received prior endocrine-based therapy and chemotherapy for unresectable or metastatic
disease. The approval by the US Food and Drug Administration (FDA) was based on 
results from the TROPION-Breast01 Phase III trial.

> **Aditya Bardia, MD, MPH, Program Director of Breast Oncology and Director of 
> Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer
> Center and Global Principal Investigator for TROPION-Breast01, said**: “Despite
> considerable progress in the HR-positive, HER2-negative metastatic breast cancer
> treatment landscape, new therapies are still needed to tackle the frequent and
> complex challenge of disease progression after endocrine and initial chemotherapy.
> The approval of datopotamab deruxtecan, a novel TROP2-directed antibody drug conjugate,
> marks a major therapeutic milestone and provides patients with metastatic breast
> cancer a new treatment alternative to conventional chemotherapy.”

> **Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit,
> AstraZeneca, said**: “With this first approval of _Datroway_ in the US, we continue
> to deliver on our ambition for antibody drug conjugates to improve upon and replace
> conventional chemotherapy for the treatment of multiple cancers. We are proud 
> to bring _Datroway_ to people living with metastatic HR-positive, HER2-negative
> breast cancer, and this approval marks the eighth new medicine of the 20 we have
> set out to deliver across AstraZeneca by 2030.”

> **Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi
> Sankyo, Inc., said**: “The approval of _Datroway_ provides patients with HR-positive,
> HER2-negative breast cancer previously treated with endocrine-based therapy and
> traditional chemotherapy with the opportunity to be treated with a new TROP2-directed
> antibody drug conjugate earlier in the metastatic setting. _Datroway_ is the latest
> addition to our portfolio of innovative cancer treatments and marks the fourth
> medicine from our oncology pipeline to receive approval in the US.”

> **Caitlin Lewis, Senior Vice President of Strategy & Mission, Living Beyond Breast
> Cancer, said**: “Only one in three patients with metastatic HR-positive, HER2-
> negative breast cancer live more than five years following diagnosis, highlighting
> the urgent need for additional effective therapies. The approval of _Datroway_
> is a significant advance, offering patients with metastatic HR-positive breast
> cancer a new and much-needed treatment option.”

In TROPION-Breast01, _Datroway_ significantly reduced the risk of disease progression
or death by 37% compared to investigator’s choice of chemotherapy (hazard ratio [
HR] 0.63; 95% confidence interval [CI] 0.52-0.76; p<0.0001) in patients with HR-
positive, HER2-negative metastatic breast cancer as assessed by blinded independent
central review (BICR). Median progression-free survival (PFS) was 6.9 months in 
patients treated with _Datroway_ versus 4.9 months with chemotherapy.

The safety profile of _Datroway_ was consistent with the known profile of this medicine
with no new safety concerns identified. In the _Datroway_ arm, the interstitial 
lung disease (ILD) rate was 4.2% and the majority of events were low grade.

_Datroway_ is a specifically engineered TROP2-directed antibody drug conjugate (
ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised
by AstraZeneca and Daiichi Sankyo.

Additional regulatory submissions for _Datroway_ in breast cancer are under review
in the EU, China and other regions.

_AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop
and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and Datroway in
July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each
ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and
Datroway.** **_

Share on:
